InfuSystem price target raised to $14 from $13 at Roth Capital

Roth Capital raised the firm’s price target on InfuSystem (INFU) to $14 from $13 and keeps a Buy rating on the shares. The company’s Q3 results were in-line with revenue expectations and above on earnings, with the core Oncology business in Patient Services continuing to perform and management remaining focused on executing opportunities that improve profitability, the analyst tells investors in a research note. The firm said that while it reduced its forward revenue expectations, it increased its adjusted EBITDA and EPS estimates slightly, with the higher estimates and lower share count from buybacks resulting in the new price target